A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.

Autor: Chellapandian D; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.; Blood and Marrow Transplant Program, Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Hines MR; Division of Critical Care, Department of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee., Zhang R; Hematology and Oncology Center, Beijing Children's Hospital, Beijing, China., Jeng M; Division of Pediatric Hematology/Oncology, Lucile Packard Children's Hospital Stanford, Palo Alto, California., van den Bos C; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands., Santa-María López V; Department of Pediatric Hematology/Oncology, Sant Joan de Deu Hospital, Barcelona, Spain., Lehmberg K; Department of Paediatric Haematology/Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Sieni E; Department of Paediatric Haematology/Oncology, Meyer Children's University Hospital, Florence, Italy., Wang Y; Department of Medical Oncology, Beijing Friendship Hospital, Beijing, China., Nakano T; Pediatric Hematology/Oncology, Children's Hospital Colorado, University of Colorado School of Medicine, Denver, Colorado., Williams JA; Division of Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, Arizona., Fustino NJ; Pediatric Hematology/Oncology, Blank Children's Hospital, Des Moines, Iowa., Astigarraga I; Department of Paediatric Haematology/Oncology, BioCruces Health Research Institute, Cruces University Hospital, Bizkaia, Spain., Dunkel IJ; Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Abla O; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada., van Halteren AGS; Immunology Laboratory, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands., Pei D; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee., Cheng C; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee., Weitzman S; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada., Sung L; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada., Nichols KE; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2019 Mar 15; Vol. 125 (6), pp. 963-971. Date of Electronic Publication: 2018 Dec 06.
DOI: 10.1002/cncr.31893
Abstrakt: Background: Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm characterized by the presence of abnormal CD1a-positive (CD1a + )/CD207 + histiocytes. Hemophagocytic lymphohistiocytosis (HLH) represents a spectrum of hyperinflammatory syndromes typified by the dysregulated activation of the innate and adaptive immune systems. Patients with LCH, particularly those with multisystem (MS) involvement, can develop severe hyperinflammation mimicking that observed in HLH. Nevertheless, to the authors' knowledge, little is known regarding the prevalence, timing, risk factors for development, and outcomes of children and young adults who develop HLH within the context of MS-LCH (hereafter referred to LCH-associated HLH).
Methods: To gain further insights, the authors conducted a retrospective, multicenter study and collected data regarding all patients diagnosed with MS-LCH between 2000 and 2015.
Results: Of 384 patients with MS-LCH, 32 were reported by their primary providers to have met the diagnostic criteria for HLH, yielding an estimated 2-year cumulative incidence of 9.3% ± 1.6%. The majority of patients developed HLH at or after the diagnosis of MS-LCH, and nearly one-third (31%) had evidence of an intercurrent infection. Patient age <2 years at the time of diagnosis of LCH; female sex; LCH involvement of the liver, spleen, and hematopoietic system; and a lack of bone involvement each were found to be independently associated with an increased risk of LCH-associated HLH. Patients with MS-LCH who met the criteria for HLH had significantly poorer 5-year survival compared with patients with MS-LCH who did not meet the criteria for HLH (69% vs 97%; P < .0001).
Conclusions: Given its inferior prognosis, further efforts are warranted to enhance the recognition and optimize the treatment of patients with LCH-associated HLH.
(© 2018 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: